ReNeuron Group PLC (LSE:RENE) - Share price - Overview

Stock Report

ReNeuron Group PLC RENE

Last Price
GBX1.75

Day Change
-0.05|-2.78%

As of 21/07/2017
16:35:00 BST | GBX
Minimum 15 Minutes Delay.

Last Close1.80p
Day Range1.71 - 1.77
Mkt Cap56.96Mil
52-Wk Range1.60 - 3.68
Yield %0.00
ISINGB00B0DZML60
Volume2,017,429
P/E-3.90
P/S1,750.00
P/CF-3.94

Share Price

Total Returns 21/07/2017

 Chg (%)  
More ...
ReNeuron Group PLC-5.41 
FTSE 100 TR GBP0.28
 
Financials
201520162017
More ...
Income Statement
Turnover0.030.03-
Operating Profit-10.39-13.72-
Net Profit-8.91-11.35-
Reported EPS-0.50-0.40-
Balance Sheet
Current Assets14.0564.89-
Non Current Assets2.036.96-
Total Assets16.0971.86-
Current Liabilities2.354.20-
Total Liabilities2.954.20-
Total Equity13.1467.66-
Cash Flow
Operating Cash Flow-9.12-11.92-
Net Change in Cash-2.545.04-
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2018-31.99-0.93--1.93---
2019-34.85-1.00--1.80---

Regulatory News

Director Dealings
TradedActionNotifierPriceAmountValue
More ...
07/02/2017PurchaseMichael Hunt2.64250,0006,600.00
14/12/2016PurchaseMr. Olav Hellebo2.88346,64410,000.00

Company Profile

ReNeuron Group PLC and its subsidiaries researches and develops therapies using stem cells. It operates in the business segment of development of cell-based therapies.

Sector

Biotechnology

Market Position

1072 of 1845 Companies

Index

FTSE AIM All Share

Outlook

(29/06/2017) "...we expect to achieve significant clinical milestones during each of the next three years"

Next Event 07/08/2017

Next annual report due
Ratios
CompSecMkt
More ...
PER (E)-1.8914.5916.35
Div Yld (E)0.003.774.05
PEG (E)0.000.500.96
ROCE0.00190.8310.59
Op Mrgn0.00-5.254.04
EPS Grwth0.0036.7930.32
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanMr. John Berriman
Chief Executive OfficerMr. Olav Hellebo
Chief Financial Officer & Company SecretMichael Hunt
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.